Undercarboxylated Osteocalcin and Its Associations With Bone Mineral Density, Bone Turnover Markers, and Prevalence of Osteopenia and Osteoporosis in Chinese Population: A Cross-Sectional Study

Yang Xu1†, Li Shen2†, Lianyong Liu3*, Zhenlin Zhang1,2* and Weiwei Hu1*

1 Shanghai Clinical Research Center of Bone Disease, Department of Osteoporosis and Bone Diseases, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China, 2 Clinical Research Center, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China, 3 Department of Endocrinology, Pudong Hospital of Pudong New District, Shanghai, China

Objective: Undercarboxylated osteocalcin (ucOC) is one form of osteocalcin lacking full carboxylation, which plays an important role in bone homeostasis, glucose homeostasis, and energy metabolism. Our aim is to obtain the profile of serum ucOC level according to gender and age and explore its associations with bone mineral density (BMD), bone turnover markers (BTMs), and prevalence of osteopenia and osteoporosis in the Chinese population.

Methods: This is a cross-sectional study with 900 subjects, composed of 431 men and 469 women. Clinical information was collected, and BMD values of the lumbar spine (L1–4), left femoral neck, and total hip were scanned. Biochemical markers including hepatic and renal function, serum calcium, serum phosphorus, procollagen type I N-propeptide (P1NP) β-CrossLaps of type I collagen-containing cross-linked C-telopeptide (β-CTX) intact parathyroid hormone (PTH), 25-hydroxyvitamin D (25OHD), and ucOC were measured.

Results: We found that the median ucOC level was higher in men than women [men, 2.6 ng/ml; women, 1.6 ng/ml; p < 0.001]. The profile according to age showed that ucOC levels were the lowest at the age of 40–49 years in both men [2.55 ng/ml (95% CI = 1.96–3.13 ng/ml)] and women [1.57 ng/ml (95% CI = 1.12–2.03 ng/ml)]; in patients younger than 49 years, they decreased with age; then over 50 years, they quickly increased. Furthermore, we found that a higher ucOC level was correlated with lower BMD values at the lumbar spine (men, r = −0.128, p = 0.013; women, r = −0.321, p < 0.001), femoral neck (men, r = −0.095, p = 0.062; women, r = −0.260, p < 0.001), and total hip (men, r = −0.123, p = 0.015; women, r = −0.209, p < 0.001) and higher P1NP (men, r = 0.307, p < 0.001; women, r = 0.239, p < 0.001) and β-CTX (men, r = 0.169, p = 0.001; women,
have found that ucOC levels were positively correlated with
hormonally active isoform in the regulation of glucose
sensitive to vitamin K status but also functions as a
indicated that ucOC not only is a nutritional biomarker
however, there were no age-related studies on ucOC levels in
relationship between ucOC and age in Australian adult men;

shown that ucOC is a useful marker to identify the increased
studies have demonstrated that higher serum ucOC levels were
correlated with poor bone status in women. Furthermore, some
revealed that vitamin K de
of femoral neck BMD in older women. Natsumi et al. (21)
that serum ucOC predicted the risk of hip fracture independent
reduced af
amount of OC in circulation, 40%
af
residues of OC undergo carboxylation mediated by vitamin-K-
lacking carboxylation at one or more sites (13, 14). Of the total
carboxylated OC (cOC) and undercarboxylated OC (ucOC)
degree of carboxylation, OC presents in two forms: fully
Specially synthesized and secreted by osteoblasts, OC is an
lacking carboxylation at one or more sites (13, 14). Of the total
carboxylated OC (cOC) and undercarboxylated OC (ucOC)
degree of carboxylation, OC presents in two forms: fully
Specially synthesized and secreted by osteoblasts, OC is an
lacking carboxylation at one or more sites (13, 14). Of the total
carboxylated OC (cOC) and undercarboxylated OC (ucOC)
degree of carboxylation, OC presents in two forms: fully
Specially synthesized and secreted by osteoblasts, OC is an
lacking carboxylation at one or more sites (13, 14). Of the total
carboxylated OC (cOC) and undercarboxylated OC (ucOC)
degree of carboxylation, OC presents in two forms: fully
Specially synthesized and secreted by osteoblasts, OC is an
lacking carboxylation at one or more sites (13, 14). Of the total

Keywords: undercarboxylated osteocalcin, bone mineral density, bone turnover markers, osteopenia, osteoporosis

INTRODUCTION

Osteopenia and osteoporosis are common diseases worldwide, which are associated with increased fracture risk, especially in the aging population (1–4). Early detection and intervention for individuals with osteopenia or osteoporosis may effectively reduce the socioeconomic burden caused by fractures (1, 4, 5). Bone mineral density (BMD) is used as an important indicator for the diagnosis of osteopenia and osteoporosis, while bone turnover markers (BTMs) are a useful adjunct for therapeutic monitoring (6, 7). Osteocalcin (OC) is one of the traditional BTMs, which reflects skeletal status and bone remodeling (8, 9). Specially synthesized and secreted by osteoblasts, OC is an abundant non-collagenous protein (10). During the process of post-translational modification, 17, 21, and 24 glutamic acid residues of OC undergo carboxylation mediated by vitamin-K-dependent γ-glutamyl carboxylase (GGCX), which leads to a conformational change with stable α-helical portion and greater affinity for calcium and hydroxyapatite (11, 12). According to the degree of carboxylation, OC presents in two forms: fully carboxylated OC (cOC) and undercarboxylated OC (ucOC) lacking carboxylation at one or more sites (13, 14). Of the total amount of OC in circulation, 40%–60% is ucOC.

Recently, Smith et al. (15) revealed the “U shaped” relationship between ucOC and age in Australian adult men; however, there were no age-related studies on ucOC levels in Chinese men or women. In addition, recent advances have indicated that ucOC not only is a nutritional biomarker sensitive to vitamin K status but also functions as a hormonally active isoform in the regulation of glucose homeostasis and energy metabolism (16). Recent studies have shown that ucOC is a useful marker to identify the increased metabolic syndrome risk and a potential therapeutic target for cardiovascular diseases (17–19). Regarding the field of bone homeostasis, ucOC is released into circulation due to its reduced affinity to the bone matrix. Vergnaud et al. (20) found that serum ucOC predicted the risk of hip fracture independent of femoral neck BMD in older women. Natsumi et al. (21) revealed that vitamin K deficiency and high serum ucOC were correlated with poor bone status in women. Furthermore, some studies have demonstrated that higher serum ucOC levels were associated with lower BMD in women (22–24). Yamauchi et al. (25) have found that ucOC levels were positively correlated with
urinary type I collagen cross-linked-N-telopeptide (uNTX), but not BMD in postmenopausal women. Most of the research is performed in women, and there have been few reports on correlations of serum ucOC with BMD and BTMs in men. Although a higher ucOC level was found in individuals with osteoporosis, it is needed to further investigate the relationship between the ucOC level and prevalent osteopenia and osteoporosis (26).

Therefore, in this cross-sectional study, we determined how ucOC levels change with gender and age in the Chinese population and defined the associations of ucOC with BMD, BTMs, and the prevalence of osteopenia and osteoporosis in both Chinese men and women.

MATERIALS AND METHODS

Study Population

This study was approved by the Ethics Committee of the Shanghai Jiao Tong University Affiliated Sixth People’s Hospital. From November 2017 to March 2020, 934 individuals were recruited from the outpatient clinic, and written informed consent was obtained from all the participants. All participants were evaluated by a questionnaire about their medical history and fracture history, physical examination, and routine serum measurements including hepatic and renal function and serum calcium and phosphorus. Among the 934 participants, subjects with following conditions were excluded: 1) could not complete the questionnaire, physical examination, or routine serum measurements independently; 2) diseases affecting bone metabolism, including osteogenesis imperfecta, Paget’s disease of bone, rheumatoid arthritis, primary hyperparathyroidism, diabetes mellitus, or malignant tumors; 3) medication use affecting bone metabolism, including treatment with synthetic steroid hormones, epinephrine, denosumab, bisphosphonate, teriparatide, estrogen, or other anti-osteoporosis drugs in the past 1 year; 4) medication use including antacids containing aluminum, warfarin, and thrombolytic drugs; 5) serious primary diseases affecting the cardiovascular, pulmonary, hematopoietic, gastrointestinal, renal, or nervous systems or mental state; 6) abnormal biochemical measurements, including alkaline
phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (Cr), uric acid (UA), blood urea nitrogen (BUN), serum calcium, and phosphorus. Eight subjects were excluded because they had taken bisphosphonate or teriparatide to treat osteoporosis, and another 26 subjects were excluded because of abnormal hepatic or renal function or serum calcium or phosphorus level. Finally, a total of 900 participants (aged 17–89 years; men, 431; women, 469) were enrolled in the study.

**Biochemical Measurements**

Blood samples were collected from fasting participants in the morning from 7:00 a.m. to 10:00 a.m., and serum aliquots were stored at −80°C until being assayed. Routine hepatic and renal functions, including ALP, ALT, AST, Cr, UA, and BUN, and serum calcium and phosphorus were measured using a cobas c 701 automatic biochemistry analyzer (Roche Diagnostic GmbH, Basel, Switzerland). All the bone metabolism markers were measured by electrochemiluminescence immunoassay with the following kits (Roche Diagnostic GmbH): total P1NP kit for procollagen type 1 N-propeptide (P1NP), β-CrossLaps kit for b-CrossLaps of type I collagen-containing cross-linked C-telopeptide (β-CTX), intact PTH kit for parathyroid hormone (PTH), and vitamin D total kit for 25-hydroxyvitamin D (25OHD). Serum ucOC was measured by ELISA using monoclonal mouse anti-GlucO as the capture antibody, peroxidase-labeled monoclonal mouse anti-Glu-OC as the detection antibody, and tetramethylbenzidine for chromogenic reaction (Glu-OC kit, Takara Bio Inc., Otsu, Japan). The intra- and interassay coefficients of variation (CVs) were 5.2% and 8.3%, respectively.

**Other Measurements**

Height and body weight were measured on an ultrasonic body scale. Body mass index (BMI) was calculated by dividing weight by squared height. The BMD at the lumbar spine (L1–4), left femoral neck, and total hip was scanned using dual-energy X-ray absorptiometry (DAX, Lunar Corp., Cambridge, MA, USA). Then, according to the WHO criteria for the classification of osteopenia and osteoporosis based on T or Z values of BMD and osteoporotic fractures, all the subjects were divided into two groups (27). The group of osteopenia or osteoporosis was assessed as follows: 1) T values of BMD at the lumbar spine, femoral neck, and total hip in the elderly men over 50 years or postmenopausal women < −1.0; 2) Z values of BMD at the lumbar spine, femoral neck, and total hip in men under 50 years or premenopausal women ≤ −2.0; and 3) with osteoporotic fractures in hip or spine and age over 50 years. Then, the remaining patients were considered as the group of normal BMD.

**Statistical Analysis**

The Kolmogorov–Smirnov test was used to measure the normality of the data. The skewed distributed variables were expressed as median (interquartile range) and categorical variables as frequency (%). The Mann–Whitney U test was used to compare the differences between groups with non-normally distributed data, and the χ² test or Fisher’s exact test was used for categorical variables. Partial correlation analysis was used to examine the associations of ucOC level with BMD and BTMs after adjusting for age, BMI, Cr, and 25OHD. The logistic regression model was used to estimate the odds ratio (OR) with 95% CIs for osteopenia or osteoporosis.

All statistical analyses were performed in the SPSS software (version 26.0, SPSS Inc. of IBM, USA) and R statistical software (version 4.0.2, R Foundation for Statistical Computing). A two-tailed statistical measure was performed, with a p < 0.05 considered statistically significant.

**RESULTS**

**General Characteristics of the Study Population**

The basic characteristics of the 900 participants are shown in Table 1. All the participants (men, 431; women, 469) had a median age of 48.0 years (interquartile range, 32.0–65.0 years), a median BMI of 22.9 kg/m² (interquartile range, 20.8–25.2 kg/m²), and a median serum ucOC level of 2.0 ng/ml (interquartile range, 0.9–3.9 ng/ml).

**The Profile of Serum Undercarboxylated Osteocalcin Level According to Gender and Age**

From the 900 participants, men had a higher serum ucOC level than women after adjusting for age, BMI, Cr, and 25OHD [men, 2.6 ng/ml (interquartile range, 1.3–4.7 ng/ml); women, 1.6 ng/ml (interquartile range, 0.7–3.1 ng/ml); p < 0.001] (Table 1). In the line chart with the profile of serum ucOC according to age, after adjusting for BMI, Cr, and 25OHD, ucOC levels were the lowest in the age group of 40–49 years in both men [2.55 ng/ml (95% CI = 1.96–3.13 ng/ml)] and women [1.57 ng/ml (95% CI = 1.12–2.03 ng/ml)] (Supplementary Figure S1). In men, the ucOC level decreased with increasing age until 49 years and then quickly increased over the age of 50 years (Table 2). A similar tendency was also observed in women (Table 2).

**The Associations of Serum Undercarboxylated Osteocalcin With Bone Mineral Density and Bone Turnover Markers**

After age, BMI, Cr, and 25OHD were adjusted, partial correlation analysis revealed that a higher ucOC level was correlated with lower BMD at the lumbar spine (men, r = −0.128, p = 0.013; women, r = −0.321, p < 0.001), femoral neck (men, r = −0.095, p = 0.062; women, r = −0.260, p < 0.001), and total hip (men, r = −0.123, p = 0.015; women, r = −0.209, p < 0.001) in both men and women (Table 3). Additionally, a higher ucOC level was found to be correlated with higher P1NP levels in both men and women (men, r = 0.307, p < 0.001; women, r = 0.239, p < 0.001) and β-CTX (men, r = 0.169, p < 0.001; women, r = 0.354, p < 0.001) (Table 3). Since vitamin D is one of the main drivers of bone mineralization, we further evaluated the
TABLE 1 | Basic characteristics of the 900 participants.

| Characteristics          | Total sample (n = 900) | Men (n = 431) | Women (n = 469) | p     | p*     |
|--------------------------|------------------------|---------------|-----------------|-------|--------|
| Age (years)              | 48.0 (32.0–65.0)       | 52.0 (32.0–69.0) | 46.0 (33.0–62.0) | 0.006 | –      |
| BMI (kg/m²)              | 22.9 (20.8–25.2)       | 23.7 (21.6–26.0) | 22.2 (20.3–24.4) | <0.001 | –      |
| Cr (μmol/L)              | 72.0 (63.0–84.0)       | 83.0 (72.0–93.0) | 65.0 (59.0–73.0) | <0.001 | –      |
| 25OHD (μg/L)             | 21.4 (15.0–29.0)       | 21.0 (16.0–29.0) | 22.0 (15.0–29.5) | 0.706  | –      |
| Lumbar spine BMD (g/cm²) | 1.01 (0.98–1.15)       | 1.01 (0.91–1.15) | 1.00 (0.88–1.15) | 0.533  | 0.542  |
| Femoral neck BMD (g/cm²) | 0.82 (0.73–0.91)       | 0.84 (0.75–0.92) | 0.81 (0.72–0.90) | 0.003  | 0.016  |
| Total hip BMD (g/cm²)    | 0.90 (0.80–0.99)       | 0.92 (0.82–1.01) | 0.89 (0.78–0.97) | <0.001 | 0.010  |
| ALP (U/L)                | 67.0 (54.0–83.0)       | 68.0 (55.0–84.0) | 66.0 (52.8–82.3) | 0.067  | 0.386  |
| ALT (U/L)                | 13.0 (9.0–19.0)        | 13.0 (9.0–19.0) | 13.0 (10.0–19.0) | 0.632  | 0.371  |
| AST (U/L)                | 19.0 (10.0–24.0)       | 20.0 (16.0–25.0) | 19.0 (15.0–23.5) | 0.072  | 0.178  |
| UA (μmol/L)              | 312.0 (262.0–372.0)    | 340.0 (279.0–405.0) | 294.0 (246.0–347.0) | <0.001 | 0.200  |
| BUN (mmol/L)             | 5.0 (4.2–6.0)          | 5.2 (4.4–6.2)    | 4.9 (4.0–5.8)    | <0.001 | <0.001 |
| Calcium (mmol/L)         | 2.42 (2.26–2.59)       | 2.35 (2.18–2.52) | 2.47 (2.34–2.64) | <0.001 | 0.001  |
| Phosphorus (mmol/L)      | 1.20 (1.04–1.35)       | 1.08 (0.96–1.23) | 1.30 (1.17–1.42) | <0.001 | <0.001 |
| P1NP (ng/ml)             | 46.3 (34.2–62.6)       | 47.0 (34.7–66.3) | 45.9 (33.8–60.6) | 0.122  | 0.892  |
| β-CTX (ng/ml)            | 0.39 (0.27–0.56)       | 0.41 (0.27–0.58) | 0.38 (0.27–0.56) | 0.311  | 0.055  |
| PTH (ng/ml)              | 39.2 (28.9–51.0)       | 36.9 (25.9–49.0) | 41.2 (31.2–52.8) | <0.001 | <0.001 |
| ucOC (ng/ml)             | 2.0 (0.9–3.9)          | 2.6 (1.3–4.7)    | 1.6 (0.7–3.1)    | <0.001 | <0.001 |

BMI, body mass index; BMD, bone mineral density; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; UA, uric acid; BUN, blood urea nitrogen; Cr, creatinine; P1NP, procollagen type 1 N-propeptide; β-CTX, β-CrossLaps of type I collagen-containing cross-linked C-telopeptide; 25OHD, 25-hydroxyvitamin D; PTH, parathyroid hormone; ucOC, undercarboxylated osteocalcin.

*Adjusted for age, BMI, Cr, and 25OHD. Significant values (p < 0.05) are presented in bold.

TABLE 2 | Means and 95% CI for the age-specific measurements of ucOC in men and women.

| age          | Men (n = 431) | Women (n = 469) |
|--------------|---------------|-----------------|
|              | ucOC          | ucOC            |
|              | Number        | Number          |
| <29          | 80            | 3.61 (2.87, 4.35)| 86            | 3.23 (2.53, 3.93) |
| 30–39        | 69            | 3.01 (2.42, 3.60)| 95            | 1.89 (1.41, 2.37) |
| 40–49        | 53            | 2.55 (1.96, 3.13)| 79            | 1.57 (1.12, 2.03) |
| 50–59        | 54            | 3.72 (2.96, 4.47)| 72            | 2.15 (1.56, 2.74) |
| 60–69        | 72            | 3.07 (2.42, 3.71)| 78            | 2.46 (1.86, 3.06) |
| ≥70          | 103           | 3.68 (3.21, 4.11)| 59            | 1.73 (1.12, 2.33) |

Adjusted for BMI, Cr, and 25OHD.

ucOC, undercarboxylated osteocalcin; BMI, body mass index; Cr, creatinine; 25OHD, 25-hydroxyvitamin D.

A correlation of ucOC with BMD and BTMs in the vitamin D-sufficient subjects (25OHD ≥ 20 μg/L; men, 239; women, 273), and it revealed similar results as above (Supplementary Table S1).

The Associations of Serum Undercarboxylated Osteocalcin With Prevalence of Osteopenia or Osteoporosis

According to WHO criteria for the classification of osteopenia and osteoporosis, we classified all participants with accessible BMD values and osteoporotic fracture information into two subgroups: one with osteopenia or osteoporosis (N = 386; men, 190; women, 196) and another subgroup with normal BMD (N = 493; men, 221; women, 272). Twenty-one subjects without exact BMD values were excluded. As shown in Table 4, the logistic regression model with age, BMI, Cr, and 25OHD adjusted revealed that a 1 – 5D increase in ucOC was associated with an OR of 1.63 and 1.70 for having osteopenia or osteoporosis in men and women, respectively (men, 95% CI = 1.25–2.13, p = 0.004; women, 95% CI = 1.19–2.42, p = 0.004), which suggested

TABLE 3 | Correlations between serum ucOC level with BMD and BTMs.

| Variables             | Men (n = 431) | Women (n = 469) |
|-----------------------|---------------|-----------------|
|                       | r      | p     | r      | p     |
| Lumbar spine BMD (g/cm²) | -0.128 | 0.013 | -0.321 | <0.001 |
| Femoral neck BMD (g/cm²) | -0.096 | 0.062 | -0.260 | <0.001 |
| Total hip BMD (g/cm²)   | -0.123 | 0.015 | -0.209 | <0.001 |
| P1NP (ng/ml)            | 0.307 | <0.001 | 0.239 | <0.001 |
| β-CTX (ng/ml)           | 0.199 | 0.001 | 0.354 | <0.001 |

Adjusted for age, BMI, Cr, and 25OHD, and significant values (p < 0.05) are presented in bold.

BMD, bone mineral density; P1NP, procollagen type 1 N-propeptide; β-CTX, β-CrossLaps of type I collagen-containing cross-linked C-telopeptide.
that a higher level of ucOC was associated with the higher risk of osteopenia or osteoporosis in both men and women.

DISCUSSION

This was a large cross-sectional study exploring the profile of serum ucOC levels according to gender and age in the Chinese population. First, we found that men had a higher serum ucOC level than women after adjusting for age, BMI, Cr, and 25OHD, which was consistent with previous studies (28–30), but some studies also showed contrary results (31). The difference may partly be attributed to the difference in the hormonal milieu between genders. Foo et al. (28) believed that female sex hormones might have a role in modulating the level of ucOC, while Hiam et al. (30) found that testosterone may mediate the differences in ucOC levels between men and women. The above discrepancies require further study to elucidate the role of sex steroids in bone metabolism and explain these sex differences. Moreover, we found that in both men and women, ucOC levels decreased with age from youth, reaching the bottom values at the age of 40–49 years, and then increased in the subsequent life. The age-related changes in serum ucOC in the current study were consistent with the “U-shaped” relationship between ucOC and age in adult men proposed by Smith et al. (15). Perhaps due to different populations and sample sizes, the age with the lowest ucOC level in our study was 5 years earlier than that in Smith’s study. Similar age-related changes were also reported in other BTMs, like total OC, P1NP, and β-CTX, which may be related to different bone statuses during the life span (32). In youth, the higher ucOC levels might be correlated with beneficial increases in bone formation and suggested that the skeletal system had not yet reached maturity, while in the elderly, it might reflect the imbalance or uncoupling of bone resorption and formation and be correlated with bone loss (33).

Subsequently, we explored the associations of ucOC with BMD and BTMs in the Chinese population. First, we found that a higher ucOC level was correlated with lower BMD at the lumbar spine, femoral neck, and total hip in both men and women. Ito et al. (34) and Vergnaud et al. (20) found that ucOC was significantly and negatively correlated with femoral neck BMD, while Yamauchi et al. demonstrated that it was only negatively correlated with lumbar BMD (25). However, Liu et al. (24) considered that the increase of ucOC might be related to the changes in bone quality rather than mineral density, as they found no associations between ucOC and BMD. Our findings were similar to the results of Szulc et al. (23) and Emaus et al. (35) that elderly women with abnormally high serum ucOC have lower BMD values at all sites. Cummings et al. (36) found that a 26% decrease in femoral neck BMD of patients with abnormal levels of ucOC corresponds to a five- to sevenfold increase in hip fracture from the prospective data. Although the reason for the strong association between ucOC and BMD is not clear, the phenomenon might indicate that increased serum ucOC reflected intrinsic abnormalities of the bone matrix leading to bone loss and increased fragility. Additionally, we showed that a higher ucOC level was correlated with higher P1NP and β-CTX levels in both men and women, while Yamauchi et al. (25) demonstrated a strong and positive correlation between ucOC and uNTX in postmenopausal women. Although detailed mechanisms have not been clarified, one hypothesis may partly explain the positive correlation. When bone turnover is accelerated, markers including P1NP, β-CTX, and total OC are excessively synthesized, and greater quantities of vitamin K may be required. The relative insufficiency of vitamin K and increased OC are likely to cause increased ucOC levels (25). Since vitamin D is one of the main drivers of bone mineralization, we further evaluated the correlation of ucOC with BMD and BTMs in the vitamin D-sufficient subjects. In this study, we found that a higher ucOC level was still associated with a lower BMD and higher levels of P1NP and β-CTX.

Moreover, we found that a higher level of ucOC was associated with a higher risk of osteopenia or osteoporosis in both men and women, after adjusting for age, BMI, Cr, and 25OHD. Horiuchi et al. (26) revealed that serum ucOC level in individuals with osteopenia or osteoporosis was significantly higher than that in individuals with normal BMD, and Vergnaud et al. (20) considered that a higher ucOC level was a predictor of hip fracture in older women. However, currently, the relationship between ucOC levels and the risk of prevalent osteopenia or osteoporosis remained unclear. A hypothesis may partly explain the role of ucOC in the skeleton; that is, an abnormally high level of ucOC can reflect the accelerated bone turnover and cause bone loss and decreased BMD, which in turn leads to osteopenia or osteoporosis and serious fractures. Further

### Table 4

| Variables | Men (n = 411) | Women (n = 468) |
|-----------|--------------|-----------------|
|           | Unadjusted   | Adjusted        | Unadjusted   | Adjusted        |
| ucOC (ng/ml) | 1.46 (1.19, 1.80) | <0.001 | 1.63 (1.25, 2.13) | 0.004 | 1.07 (0.89, 1.29) | 0.461 | 1.70 (1.19, 2.42) | 0.004 |
| P1NP (ng/ml) | 1.27 (0.98, 1.65) | 0.071 | 1.55 (1.07, 2.30) | 0.019 | 3.91 (2.67, 5.73) | <0.001 | 2.47 (1.38, 4.45) | 0.003 |
| β-CTX (ng/ml) | 0.68 (0.54, 0.87) | 0.002 | 1.10 (0.87, 1.37) | 0.462 | 3.77 (2.76, 5.14) | <0.001 | 3.13 (1.92, 5.10) | <0.001 |

For the unadjusted models, ucOC, P1NP, and β-CTX were analyzed separately; for adjusted model, age, BMI, Cr, and 25OHD were adjusted.

ucOC, undercarboxylated osteocalcin; P1NP, procollagen type 1 N-propeptide; β-CTX, β-CrossLaps of type I collagen-containing cross-linked C-telopeptide; BMI, body mass index; Cr, creatinine; 25OHD, 25-hydroxyvitamin D.
randomized controlled studies or prospective studies are needed to reveal the specific causality and mechanism.

There were also some limitations in our study. First, some important variables were lacking, such as vitamin K, which acted as a coenzyme of carboxylase and catalyzed the carboxylation of OC. Our study did not evaluate the effect of vitamin K. Second, we used the commercial ELISA kit to measure the level of ucOC in serum, which was not considered the gold standard. Therefore, the serum ucOC level in this study could not reflect the levels measured by other technologies. Third, this is a cross-sectional study; thus, the proven causality between the ucOC, and BMD, BTMs, and prevalence of osteopenia and osteoporosis was limited. Therefore, further studies with a large sample size, wide age span, appropriate gender distribution, and unified measurement are still needed.

In conclusion, we first revealed the profile of the serum ucOC level according to gender and age in the Chinese population and demonstrated the associations of ucOC with BMD, BTMs, and the risk of prevalent osteopenia or osteoporosis. Our findings may provide a clue to elucidate the function of ucOC in bone metabolism.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the ethics committee of the Human Research of the Shanghai Jiao Tong University Affiliated Sixth People’s Hospital. The patients/participants provided their written informed consent to participate in this study.

**REFERENCES**

1. Black DM, Rosen CJ. Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med (2016) 374(3):254-62. doi: 10.1056/NEJMc1513724
2. Compton JE, McCung MR, Leslie WD. Osteoporosis. Lancet (2019) 393 (10169):364-76. doi: 10.1016/S0140-6736(18)32112-3
3. Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, et al. Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures. Arch Intern Med (2004) 164(10):1108-12. doi: 10.1001/archinte.164.10.1108
4. Khosla S, Melton LJ3rd. Clinical Practice. Osteopenia. N Engl J Med (2007) 356(22):2399-300. doi: 10.1056/NEJMcp070341
5. Si L, Winzenberg TM, Jiang Q, Chen M, Palmer AJ. Projection of Osteoporosis-Related Fractures and Costs in China: 2010-2050. Osteoporos Int (2015) 26(7):1929–37. doi: 10.1007/s00198-015-3093-2
6. Vaskaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A, et al. Markers of Bone Turnover for the Prediction of Fracture Risk and Monitoring of Osteoporosis Treatment: A Need for International Reference Standards. Osteoporos Int (2011) 22(2):391-420. doi: 10.1007/s00198-010-1501-1
7. Greenblatt MB, Tsai JN, Wein MN. Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease. Clin Chem (2017) 63(2):464–74. doi: 10.1373/clinchem.2016.259085
8. Delmas PD. Biochemical Markers of Bone Turnover for the Clinical Investigation of Osteoporosis. Osteoporos Int (1993) 3(Suppl 1):81–6. doi: 10.1007/BF01621873
9. Kruse K, Kracht U. Evaluation of Serum Osteocalcin as an Index of Altered Bone Metabolism. Eur J Pediatr (1986) 145(1-2):27–33. doi: 10.1007/BF0041848
10. Neve A, Corrado A, Cantatore FP. Osteocalcin: Skeletal and Extra-Skeletal Effects. J Cell Physiol (2013) 228(6):1149–53. doi: 10.1002/jcp.24278
11. Pearson DA. Bone Health and Osteoporosis: The Role of Vitamin K and Potential Antagonism by Anticoagulants. Nutr Clin Pract (2007) 22(5):517–44. doi: 10.1177/0884533607022005517
12. Lee AJ, Hodge S, Eastell R. Measurement of Osteocalcin. Ann Clin Biochem (2000) 37(Pt 4):422–46. doi: 10.1177/000456320003700402
13. Gundberg CM, Nieman SD, Abrams S, Rosen H. Vitamin K Status and Bone Health: An Analysis of Methods for Determination of Undercarboxylated Osteocalcin. J Clin Endocrinol Metab (1998) 83(9):3258–66. doi: 10.1210/jcem.83.9.5126
14. Hauschka PV, Carr SA. Calcium-Dependent Alpha-Helical Structure in Osteocalcin. Biochemistry (1982) 21(10):2538–47. doi: 10.1021/bi00535a038
15. Smith C, Voisin S, Al Saedi A, Phu S, Brennan-Speranza T, Parker L, et al. Osteocalcin and Its Forms Across the Lifespan in Adult Men. Bone (2020) 130:115085. doi: 10.1016/j.bone.2019.115085

**AUTHOR CONTRIBUTIONS**

Study design: YX and ZZ. Study conduct: YX, LL, and WH. Data analysis and interpretation: YX and LS. Manuscript draft: YX and LS. Manuscript content revision: WH, ZZ, and LL. YX and LS contributed equally to this work. All authors contributed to the article and approved the submitted version.

**FUNDING**

This study was supported by the National Key R&D Program of China (2018YFA0800801), Shanghai Municipal Key Clinical Specialty, Key Specialty Construction Project of Pudong Health and Family Planning Commission of Shanghai (PWZzk2017-29), Outstanding Leaders Training Program of Pudong Health Bureau of Shanghai (PWRI2018-02), and Science Foundation of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital (lygl202101).

**ACKNOWLEDGMENTS**

We are grateful to all participants in this study.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2022.843912/ full#supplementary-material
16. Kanazawa I, Yamaguchi T, Yamauchi M, Yamamoto M, Kurioka S, Yano S, et al. Serum Undercarboxylated Osteocalcin Was Inversely Associated With Plasma Glucose Level and Fat Mass in Type 2 Diabetes Mellitus. Osteoporos Int (2011) 22(1):187–94. doi: 10.1007/s00198-010-1184-7

17. Liu X, Yeap BK, Brock KE, Levering I, Golledge J, Flicker L, et al. Associations of Osteocalcin Forms With Metabolic Syndrome and Its Individual Components in Older Men: The Health in Men Study. J Clin Endocrinol Metab (2021) 106(9):x3506–18. doi: 10.1210/clinem/dgab358

18. Riquelme-Gallego B, Garcia-Molina L, Cano-Ibáñez N, Sánchez-Delgado G, Andújar-Vera F, García-Fontana C. Circulating Undercarboxylated Osteocalcin as Estimator of Cardiovascular and Type 2 Diabetes Risk in Metabolic Syndrome Patients. Sci Rep (2020) 10(1):1840. doi: 10.1038/s41598-020-6760-7

19. Iki M, Yura A, Fujita Y, Kouda K, Tamaki J, Tachiki T, et al. Circulating Osteocalcin Levels Were Not Significantly Associated With the Risk of Incident Type 2 Diabetes Mellitus in Elderly Japanese Men: The Fuijwara-Kyo Osteoporosis Risk in Men (FORMEN) Cohort Study. Bone (2021) 147:115912. doi: 10.1016/j.bone.2021.115912

20. Vergnaud P, Garnero P, Meunier PJ, Bréart G, Kamaragi K, Delmas PD. Undercarboxylated Osteocalcin Measured With A Specific Immunoassay Predicts Hip Fracture in Elder Women: The EPDOS Study. J Clin Endocrinol Metab (1997) 82(3):719–24. doi: 10.1210/jcem.82.3.8305

21. Tanaka N, Arima K, Nishimura T, Tomita Y, Mizukami S, Okabe T, et al. Vitamin K Deficiency, Evaluated With Higher Serum ucOC, was Correlated With Poor Bone Status in Women. J Physiol Anthropol (2020) 39(1):9. doi: 10.1186/s40101-020-00221-1

22. Kim SM, Kim KM, Kim BT, Joo NS, Kim KN, Lee DJ. Correlation of Undercarboxylated Osteocalcin (ucOC) Concentration and Bone Density With Age in Healthy Korean Women. J Korean Med Sci (2010) 25(8):1171–5. doi: 10.3346/jkms.2010.25.8.1171

23. Szulc P, Arlot M, Chapuy MC, Duboeuf F, Meunier PJ, Delmas PD. Serum Undercarboxylated Osteocalcin Correlates With Hip Bone Mineral Density in Elderly Women. J Bone Miner Res (1994) 9(10):1591–5. doi: 10.1002/jbr.265091012

24. Liu G, Peacock M. Age-Related Changes in Serum Undercarboxylated Osteocalcin and Its Relationships With Bone Density, Bone Quality, and Hip Fracture. Calcif Tissue Int (1998) 62(4):286–9. doi: 10.1007/s002239900432

25. Yamauchi M, Yamaguchi T, Nawata K, Takaoka S, Sugimoto T. Relationships Between Undercarboxylated Osteocalcin and Vitamin K Intakes, Bone Turnover, and Bone Mineral Density in Healthy Women. Clin Nutr (2010) 29(6):761–5. doi: 10.1016/j.clnut.2010.02.010

26. Horiiuchi T, Kazama H, Araki A, Inoue J, Hossi T, Onouchi T, et al. Impaired Gamma Carboxylation of Osteocalcin in Elderly Women With Type II Diabetes Mellitus: Relationship Between Increase in Undercarboxylated Osteocalcin Levels and Low Bone Mineral Density. J Bone Miner Metab (2004) 22(3):236–40. doi: 10.1007/00774-003-0473-z

27. Camacho PM, Petak SM, Binkley N, Diab DI, Elderly LS, Farooki A, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 Update. Endocr Pract (2020) 26(Suppl 1):1–46. doi: 10.4158/GL-2020-0524SUPPL

28. Foo JP, Aronis KN, Chamberland JP, Thakkar B, Hamnvik OP, Brinkoetter M, et al. Gender Dimorphism and Lack of Day/night Variation or Effects of Energy Deprivation on Undercarboxylated Osteocalcin Levels in Humans. Obes (Silver Spring) (2013) 21(12):E527–32. doi: 10.1002/oby.20453

29. Dušková M, Kolarová L, Janíčková H, Pospíšilová H, Stárka L. Are There Sex Differences in the Reaction of Undercarboxylated Osteocalcin to Hypoglycemia? Physiol Res (2020) 69(Suppl 2):S315–20. doi: 10.33549/physiolres.934520

30. Hiam D, Landen S, Jacques M, Voisin S, Alvarez-Romero J, Byrnes E, et al. Osteocalcin and Its Forms Respond Similarly to Exercise in Males and Females. Bone (2021) 144:115818. doi: 10.1016/j.bone.2021.115818

31. Furusyo N, Ichiba T, Hayashi T, Ikezaki H, Toyoda K, Ogawa E, et al. The Serum Undercarboxylated Osteocalcin Level and the Diet of A Japanese Population: Results From the Kyushu and Okinawa Population Study (KOPS). Endocrin (2013) 43(3):635–42. doi: 10.1016/j.endocr2012001-9803-z

32. Hu WW, Zhang Z, He JW, Fu WZ, Wang C, Zhang H, et al. Establishing Reference Intervals for Bone Turnover Markers in the Healthy Shanghai Population and the Relationship With Bone Mineral Density in Postmenopausal Women. Int J Endocrinol (2013) 2013:513925. doi: 10.1155/2013/513925

33. Delaisse JM, Andersen TL, Kristensen HB, Jensen PR, Andreasen CM, Søe K. Re-Thinking the Bone Remodeling Cycle Mechanism and the Origin of Bone Loss. Bone (2020) 141:115628. doi: 10.1016/j.bone.2020.115628

34. Ito K, Oukawara S, Hibino Y, Imai S, Fuseki M, Bandai Y, et al. Skeletal Muscle Mass Index is Positively Associated With Bone Mineral Density in Hemodialysis Patients. Front Med (Lausanne) (2020) 7:187. doi: 10.3389/fmed.2020.00187

35. Emaus N, Nguyen ND, Almaas B, Berntsen GK, Center JR, Christensen M, et al. Serum Level of Under-Carboxylated Osteocalcin and Bone Mineral Density in Early Menopausal Norwegian Women. Eur J Nutr (2013) 52(1):49–55. doi: 10.1007/s00394-011-0285-1

36. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, et al. Bone Density at Various Sites for Prediction of Hip Fractures. The Study of Osteoporotic Fractures Research Group. Lancet (1993) 341(8837):72–5. doi: 10.1016/s0140-6736(93)92255-8

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Xu, Shen, Liu, Zhang and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.